Improving Drug Safety — A Joint Responsibility

  • Rolf Dinkel
  • Bruno Horisberger
  • Kenneth W. Tolo
Conference proceedings

Part of the Health Systems Research book series (HEALTH)

Table of contents

  1. Front Matter
    Pages I-XXI
  2. The Wolfsberg Dialogue

    1. Front Matter
      Pages 1-1
    2. Rolf Dinkel, Bruno Horisberger, Kenneth W. Tolo
      Pages 3-4
    3. W. P. von Wartburg
      Pages 5-9
  3. Welcoming Addresses

  4. Ethical Perspectives

    1. Front Matter
      Pages 21-21
    2. S. Gorovitz
      Pages 23-26
    3. Z. Bankowski
      Pages 27-35
    4. E. W. D. Young
      Pages 36-46
    5. K. M. Leisinger
      Pages 47-57
    6. Rolf Dinkel, Bruno Horisberger, Kenneth W. Tolo
      Pages 58-61
  5. Generating Knowledge About Drug Risks

    1. Front Matter
      Pages 63-63
    2. K. Strandberg
      Pages 75-79
    3. G. A. Faich
      Pages 80-85
  6. Generating Knowledge About Drug Benefits

    1. Front Matter
      Pages 87-87

About these proceedings

Introduction

As the focus on pharmaceuticals has broadened from concern for their cost and effectiveness to their real and potential risks and benefits, a critical question has been raised: whose responsibility is it to improve drug safety? In April 1990, this question became the theme for a conference at Wolfsberg, Switzerland, near the shores of Lake Constance. Called an "international dialogue conference" by its organizers, the meeting brought together leaders from the pharmaceutical industry, regulatory authorities, academia, medicine, consumer organizations and the media. Opening addresses were given by representatives of the Council for International Organizations of Medical Sciences (CIOMS), the International Federation of Pharmaceutical Manufacturers Associations (IFPMA), the Swiss International Pharmaceutical Agency, and the RAD-AR Consortium. This book documents the papers presented and discussions held at this conference, which took the topic of risks and benefits of drug therapy one step further to responsibility. It includes a rich menu of issues for those who care about the evaluation of drug therapy, the ethics behind it, the expectations of the patient, and the role of traditional and nontraditional drug safety communica­ tions. The ideas expressed here come from different parts of the world but relate to common drug safety problems, observations, and scientific assessments; they provide insights into innovative approaches, cautious changes, and desired actions. The papers in this volume are broadly divided into conceptual perspectives (ethics, how the knowledge about drug risks and benefits is generated and appraised, the expectations in drug safety) and operational perspectives (communication, discussion, and action).

Keywords

Arzneimittel Arzneitherapie Bewertung der Therapie mit Arzneimitteln Drogenrisiko/Nutzen-Bewertung Suchttherapie addiction therapy assessment drug drug safety communications ethics regulatiory fo evaluation of drug therapy regulatorische Trends research therapy wissenschaftliche Bewertung

Editors and affiliations

  • Rolf Dinkel
    • 1
  • Bruno Horisberger
    • 2
  • Kenneth W. Tolo
    • 3
  1. 1.HealthEcon Ltd.BaselSwitzerland
  2. 2.Interdisciplinary Research Centre for Pulic HealthSt. GallenSwitzerland
  3. 3.The University of Texas at AustinAustinUSA

Bibliographic information

  • DOI https://doi.org/10.1007/978-3-642-61250-3
  • Copyright Information Springer-Verlag Berlin Heidelberg 1991
  • Publisher Name Springer, Berlin, Heidelberg
  • eBook Packages Springer Book Archive
  • Print ISBN 978-3-642-64762-8
  • Online ISBN 978-3-642-61250-3
  • Series Print ISSN 1431-4002
  • About this book